Alpha Sophia
Insights

From Diagnosis to Opportunity: Turning ICD-10 Data into Pharma Sales Strategy

Isabel Wellbery •
#ICD10#PharmaStrategy
From Diagnosis to Opportunity: Turning ICD-10 Data into Pharma Sales Strategy
Summarize with AI

In pharmaceutical sales, most teams rely heavily on prescribing data to guide targeting decisions. While prescription data is valuable, it only tells part of the story—and often too late in the patient journey.

For small and mid-sized pharma teams especially, where resources are limited and precision matters, a more proactive approach is required. This is where ICD-10 diagnosis data becomes a powerful, underutilized signal.

By understanding where diagnoses are happening—not just where treatments are prescribed—commercial teams can identify earlier opportunities, uncover unmet demand, and build more effective targeting strategies.

What is ICD-10 data and why does it matter?

ICD-10 (International Classification of Diseases, 10th Revision) codes are used globally to classify and record diagnoses across healthcare systems. In the United States, these codes are embedded in claims data and provide a standardized way to track patient conditions, disease prevalence, and clinical activity.

According to the World Health Organization, ICD-10 codes are designed to enable systematic recording, analysis, and interpretation of health data across populations (https://www.who.int/standards/classifications/classification-of-diseases).

For commercial pharma teams, ICD-10 data represents something critical:

It shows where patient demand originates.

While prescribing data reflects treatment decisions, diagnosis data captures the moment a condition is identified. This distinction is important. Diagnosis often precedes treatment—and in many cases, not all diagnosed patients are treated immediately or at all.

ICD-10 vs prescribing data: understanding the difference

Pharma teams have traditionally focused on prescription (Rx) data because it directly ties to revenue. However, relying solely on prescribing data creates blind spots.

Prescription data answers:

ICD-10 diagnosis data answers:

This distinction is supported by industry research. McKinsey highlights that leading pharma organizations are increasingly incorporating real-world data, including claims and diagnosis patterns, to improve targeting and commercial execution.

For small pharma teams, this shift is particularly valuable. Instead of competing for the same known prescribers, teams can identify earlier-stage opportunities and expand their reach more efficiently.

Turning ICD-10 data into a practical sales strategy

Understanding ICD-10 data conceptually is one thing. Turning it into a repeatable, tactical sales strategy is where real value emerges.

1. Identify relevant ICD-10 codes for your indication

The first step is defining the set of ICD-10 codes that correspond to your therapy area. For example, a company focused on chronic respiratory disease might look at codes related to conditions such as COPD or asthma.

Resources like the CDC’s ICD-10-CM guidelines provide a comprehensive reference for mapping conditions to codes.

This step is foundational. If your code selection is too broad, your targeting becomes noisy. Too narrow, and you risk missing relevant providers.

2. Map diagnosis activity to healthcare providers

Once relevant codes are defined, the next step is identifying which providers are associated with those diagnoses. This typically involves analyzing claims data to determine which physicians are seeing and diagnosing patients with the target condition.

This is where many teams encounter challenges. Raw claims data is complex, fragmented, and difficult to operationalize without significant data infrastructure.

Platforms like Alpha Sophia simplify this process by directly linking diagnosis data to individual providers and their organizational context. Instead of working with abstract datasets, teams can immediately see which physicians are diagnosing patients within a specific therapeutic area.

Not all providers are equal. Some see significantly higher volumes of relevant patients, while others may represent emerging opportunities.

By analyzing ICD-10 data over time, teams can:

This allows for more precise targeting, particularly for smaller teams that need to focus on the highest-impact accounts.

4. Connect diagnosis data to healthcare systems and networks

Providers do not operate in isolation. They are part of larger healthcare systems, referral networks, and institutional structures.

A physician diagnosing patients in one facility may influence treatment decisions elsewhere within the system. Without understanding these connections, targeting remains incomplete.

Alpha Sophia addresses this by mapping providers to their affiliated hospitals, health systems, and referral networks. This enables teams to move beyond individual-level targeting and engage at the system level, which is often where key decisions are made.

5. Identify gaps between diagnosis and treatment

One of the most valuable insights from ICD-10 data comes from identifying gaps between diagnosis and prescribing behavior.

For example:

These gaps represent untapped commercial opportunities.

By combining diagnosis data with prescribing data, teams can pinpoint where education, access, or awareness efforts may have the greatest impact.

Why this approach matters for small pharma teams

Large pharmaceutical companies often rely on scale—large field teams, extensive datasets, and broad coverage. Small and mid-sized pharma companies do not have that luxury.

Instead, they need to be:

ICD-10 data provides a way to do exactly that. It allows teams to focus on providers who are actively seeing relevant patients, rather than relying solely on historical prescribing patterns.

When combined with a platform like Alpha Sophia, this approach becomes operational. Teams can access unified provider profiles that integrate diagnosis data, organizational context, and real-world activity, enabling faster and more confident decision-making.

From data to execution: embedding ICD-10 insights into your workflow

The final step is integrating these insights into day-to-day commercial workflows. Data is only valuable if it can be acted upon.

Modern commercial teams are increasingly embedding provider intelligence directly into their CRM systems and planning tools. This ensures that:

Instead of relying on static reports, teams can work from continuously updated data that reflects the current state of the market.

Diagnosis data as a competitive advantage

Pharma sales strategies are evolving. The shift from reactive targeting based on prescriptions to proactive targeting based on diagnosis data represents a meaningful competitive advantage—especially for smaller teams.

ICD-10 data provides visibility into where demand begins. It highlights providers who are seeing patients today, even if they are not yet prescribing at scale. And it uncovers gaps that represent real opportunities for growth.

By combining this data with unified provider intelligence platforms like Alpha Sophia, life sciences teams can move beyond fragmented datasets and operate with a clearer, more actionable understanding of the market.

In an increasingly complex healthcare landscape, that clarity is not just helpful—it is essential.

Further Reading

← Back to Blog